Abstract
In this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies. Based on current real-life studies and analysis of practical and economic aspects, we will analyze the potential benefits of changing CGRP-targeted treatment.
Keywords:
CGRP; Combination; Gepants; Responders; Switching.
© 2023. The Author(s).
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Calcitonin Gene-Related Peptide Receptor Antagonists* / pharmacology
-
Calcitonin Gene-Related Peptide Receptor Antagonists* / therapeutic use
-
Calcitonin Gene-Related Peptide*
-
Humans
-
Receptors, Calcitonin Gene-Related Peptide
Substances
-
Calcitonin Gene-Related Peptide Receptor Antagonists
-
Calcitonin Gene-Related Peptide
-
Receptors, Calcitonin Gene-Related Peptide
-
Antibodies, Monoclonal